FDA record · warning letter

FDA warning letter: BioDrive, Inc. (Aug 24, 2026)

On Aug 24, 2026, FDA issued a warning letter to BioDrive, Inc. of New York, NY under the subject "Dietary Supplement/Adulterated". It names glp-1 (named in the letter, no specific drug). Open: no closeout letter published as of Oct 3, 2026.

Julian CaraulaniFounder, PriceTracker GLP-1FDA record read Oct 3

Status: Open: no closeout letter published as of Oct 3, 2026.

What FDA’s record states

FDA record for the warning letter to BioDrive, Inc.
Field	What FDA’s record states	Source
Recipient	BioDrive, Inc.	FDA letter
Location	New York, NY	FDA letter
Letter date	Aug 24, 2026	FDA letter
Posted by FDA	Sep 22, 2026	FDA index
Issuing office	Human Foods Program	FDA letter
Subject	Dietary Supplement/Adulterated	FDA letter
MARCS-CMS number	731846	FDA letter
GLP-1 drugs named	GLP-1 (named in the letter, no specific drug)	FDA letter
Response letter	Not published by FDA	FDA letter
Closeout letter	Not published by FDA	FDA letter

“This letter concerns your Evolv GLP-1 Biomimetic dietary supplement. Your product labeling identifies Saccharomyces cerevisiae S288C EV-1 Peptide as a dietary ingredient.”FDA warning letter to BioDrive, Inc., Aug 24, 2026 · read the full letter on fda.gov ↗

What this is and is not.A warning letter is FDA’s statement of what it considers significant violations. It is an allegation, not a court finding, and the firm can respond. A closeout letter is posted when FDA confirms the violations were corrected.

Other GLP-1 letters FDA issued that week

Source

Every field above is copied from FDA’s page for this letter, read Oct 3, 2026. The letter on fda.gov ↗ · All 161 GLP-1 warning letters